ABVC BioPharma (ABVC) Competitors

Lexeo Therapeutics (NASDAQ:LXEO) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Which has better valuation & earnings, LXEO or ABVC?

ABVC BioPharma has lower revenue, but higher earnings than Lexeo Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	$650K	205.33	-$98.33M	-$3.30	-1.22
ABVC BioPharma	$510K	73.91	-$4.90M	-$0.13	-17.08

Do insiders & institutionals believe in LXEO or ABVC?

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Comparatively, 17.1% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer LXEO or ABVC?

Lexeo Therapeutics currently has a consensus target price of $16.60, indicating a potential upside of 312.94%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
ABVC BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to LXEO or ABVC?

In the previous week, ABVC BioPharma had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for ABVC BioPharma and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.89 beat ABVC BioPharma's score of 0.39 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, LXEO or ABVC?

Lexeo Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.

Is LXEO or ABVC more profitable?

Lexeo Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-85.86%	-68.48%
ABVC BioPharma	-963.46%	-29.62%	-14.08%

Summary

Lexeo Therapeutics beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.